J Moon1,2, S S Kumar1,3, G G Graham1,3, M T Baysari1,4, K M Williams1,3, W Chen5, A Viardot5, J R Greenfield5, R O Day6,7,8. 1. Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, New South Wales, 2010, Australia. 2. St Vincent's Hospital Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia. 3. School of Medical Science, Faculty of Medicine, University of New South Wales, Sydney, Australia. 4. Centre for Health Systems & Safety Research, Australian Institute of Health Innovation, Faculty of Medicine, Macquarie University, Sydney, Australia. 5. Diabetes and Metabolism Research Division, Garvan Institute of Medical Research, Sydney, Australia. 6. Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, New South Wales, 2010, Australia. r.day@unsw.edu.au. 7. St Vincent's Hospital Clinical School, Faculty of Medicine, University of New South Wales, Sydney, Australia. r.day@unsw.edu.au. 8. School of Medical Science, Faculty of Medicine, University of New South Wales, Sydney, Australia. r.day@unsw.edu.au.
Abstract
PURPOSE: The study aimed to (1) determine the trends in the utilisation of metformin in Australia, (2) determine the appropriateness of metformin dosing in an Australian teaching hospital and (3) gather the opinions of prescribers on the relationship between metformin dose and renal function. METHODS: National prescription data between 1990 and 2012 were accessed. A retrospective audit (2008-2012) of metformin doses and patient renal function (20 % random sample of all in-patients prescribed metformin) was conducted at St Vincent's Hospital (SVH), Sydney. Prescribers of metformin were interviewed (semi-structured; consultants at SVH) or surveyed (Australian endocrinologists) to gather their understanding of metformin dosing in relation to renal function. RESULTS: Metformin utilisation increased fivefold nationally between 1995 and 2012. Metformin tended to be under-dosed in SVH patients with normal renal function (83.5 %) and over-dosed in patients with impaired renal function (estimated glomerular filtration rate (eGFR) <30 mL/min, 50 %). Consultants indicated that metformin doses needed to be reduced in renal impairment. Most endocrinologists (61 %) were comfortable prescribing metformin down to eGFRs around 30 mL/min. CONCLUSION: The use of metformin increased greatly over the period of the study. Metformin is prescribed frequently for patients with eGFR values below the minimal level approved in the product label (60 mL/min). While prescribers expressed their understanding of the need to reduce metformin doses in patients with renal impairment, we found that metformin doses were higher than appropriate in patients with impaired renal function. Metformin may be used safely when renal function is poor provided dosage is appropriately reduced.
PURPOSE: The study aimed to (1) determine the trends in the utilisation of metformin in Australia, (2) determine the appropriateness of metformin dosing in an Australian teaching hospital and (3) gather the opinions of prescribers on the relationship between metformin dose and renal function. METHODS: National prescription data between 1990 and 2012 were accessed. A retrospective audit (2008-2012) of metformin doses and patient renal function (20 % random sample of all in-patients prescribed metformin) was conducted at St Vincent's Hospital (SVH), Sydney. Prescribers of metformin were interviewed (semi-structured; consultants at SVH) or surveyed (Australian endocrinologists) to gather their understanding of metformin dosing in relation to renal function. RESULTS:Metformin utilisation increased fivefold nationally between 1995 and 2012. Metformin tended to be under-dosed in SVH patients with normal renal function (83.5 %) and over-dosed in patients with impaired renal function (estimated glomerular filtration rate (eGFR) <30 mL/min, 50 %). Consultants indicated that metformin doses needed to be reduced in renal impairment. Most endocrinologists (61 %) were comfortable prescribing metformin down to eGFRs around 30 mL/min. CONCLUSION: The use of metformin increased greatly over the period of the study. Metformin is prescribed frequently for patients with eGFR values below the minimal level approved in the product label (60 mL/min). While prescribers expressed their understanding of the need to reduce metformin doses in patients with renal impairment, we found that metformin doses were higher than appropriate in patients with impaired renal function. Metformin may be used safely when renal function is poor provided dosage is appropriately reduced.
Entities:
Keywords:
Dosing appropriateness; Metformin; Renal function
Authors: Janna K Duong; Timothy J Furlong; Darren M Roberts; Garry G Graham; Jerry R Greenfield; Kenneth M Williams; Richard O Day Journal: Drug Saf Date: 2013-09 Impact factor: 5.606
Authors: A Melander; P Folino-Gallo; T Walley; U Schwabe; P-H Groop; T Klaukka; A Vallano; J-R Laporte; M R Gallego; M Schiappa; M Røder; J P Kampmann; A de Swaef; M Aberg; N-O Månsson; U Lindblad Journal: Diabetologia Date: 2006-07-25 Impact factor: 10.122
Authors: Weiyi Huang; Gregory M Peterson; Syed Tabish R Zaidi; Ronald L Castelino Journal: Diabetes Res Clin Pract Date: 2015-02-23 Impact factor: 5.602
Authors: Janna K Duong; Shaun S Kumar; Carl M Kirkpatrick; Louise C Greenup; Manit Arora; Toong C Lee; Peter Timmins; Garry G Graham; Timothy J Furlong; Jerry R Greenfield; Kenneth M Williams; Richard O Day Journal: Clin Pharmacokinet Date: 2013-05 Impact factor: 6.447
Authors: Kristin K Clemens; Salimah Shariff; Kuan Liu; Irene Hramiak; Jeffrey L Mahon; Eric McArthur; Amit X Garg Journal: PLoS One Date: 2015-09-03 Impact factor: 3.240